LONDON--(BUSINESS WIRE)--#Dermatology--UK based bio-pharmaceutical company SiSaf closes a $4.3million interim funding round led by Vickers Venture Partners with additional capital injections by Invest NI and Innovation Ulster Limited. SiSaf is a young, commercial stage company that develops drugs using bio-courier technology, ProSilic®, a novel method of drug delivery that is based on a patented hybrid of porous silicon and liposomes. The company plans to use the investment to accelerate the development of i.